Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HOSPITAL ANTIBIOTIC INFORMATION SYSTEM WILL BE AVAILABLE IN JANUARY

Executive Summary

HOSPITAL ANTIBIOTIC INFORMATION SYSTEM WILL BE AVAILABLE IN JANUARY from the Association for Hospital Medical Education (AHME), the organization's president, William Minogue, MD, announced at an Aug. 28 press conference in Washington. The multicomponent information program, titled "Antibiotic Management System" (AMS), covers "establishment of authoritative clinical guidelines, collection and analysis of data on antibiotic use, monitoring and control of antibiotic costs, and program implementation," Minogue said. Elements of the program are being put together by three task forces set up by AHME: one developing clinical guidelines, one developing a data system for monitoring antibiotic use practices in the hospitals, and one developing an implementation manual. Development of the program was primarily funded by Roche. Minogue said that AMS will be self-sustaining via a $250 maintenance and update charge to hospitals choosing to participate in the program. Citing the need for a comprehensive information program for hospital antibiotic use, Minogue explained that AMS "is designed to correct" problems such as "the prolonged use of antibiotics in many patients, sometimes associated with toxicity and other side effects and possibly contributing to the problem of nosocomial (hospital-acquiredj infections; mounting costs of antibiotic therapy; and the threatened loss of accreditation by a third to a half of all U.S. hospitals for failure to satisfy JCAH ]Joint Commission on Accreditation of Hospitals[ standards for antibiotic review." One of the key elements of the AMS program is the clinical guidelines manual, which "provides hospitals with a critical appraisal of the medical literature dealing with antibiotics," according to Thomas Beam, MD, Buffalo Medical Center, chairman of the task force developing the guidelines. "The guidelines provide hospitals with recommendations for prophylactic, empiric, and therapeutic use of antibiotics," Beam explained. "The efficacy, toxicity, and cost of these agents have all been given consideration in reaching recommended conclusions." Explaining the data collection and analysis component of AMS, Minogue said that participating hospitals would use a computerized system to help "monitor antibiotic use and cost, and take corrective measures." Utilizing an IBM software program, the hospitals will have a "self-contained analysis system so they can manage the massive information" on antibiotic use within the hospital. The AMS program is currently undergoing a six-month pilot test in six U.S. hospitals, the results of which will be included in the implementation manual.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel